Viatris OTC business acquired by Cooper Consumer Health
Cooper Consumer Health acquired Viatris OTC business, an Europe consumer health / otc pharmaceuticals brand, on Oct 1, 2023.
Transaction summary
- Target
- Viatris OTC business
- Acquirer
- Cooper Consumer Health
- Seller
- Viatris
- Announced
- 2023-10-01
- Geography
- Europe
- Tags
- ConsumerConsumer HealthConsumer Health / OTC PharmaceuticalsOTC MedicinesPharmaceutical Manufacturing
- Type
- Acquisition
- Deal type
- Control
- Stake acquired
- -
- First added
- 2026-06-19
- Latest update
- 2026-07-12
Value and multiples
100% enterprise value
EUR 1.9B
100% enterprise value | EUR
Basis: Public source
Reported price is assumed to be 100% EV unless stated otherwise. Partial-stake estimates are qualified in the basis notes.
Approx. $2.1B USD using FX date 2023-09-29 at 1.0594 EUR/USD.
EV / revenue
-
Period: Undisclosed
Basis: Public source
EV / EBITDA
-
EBITDA basis not stated
Basis: Public source
Amounts paid and other reported values
Original reported amounts and bases; a stake payment is distinct from the estimated whole-company valuation.
Consideration: EUR 1.9B
Official Viatris Form 8-K: EUR 1.85 billion cash at closing plus up to EUR 100 million contingent cash consideration.
Basis
- EUR 1.9bn consideration is treated as publicly disclosed or derived directly from public source data.
- Valuation covers 100% of the target; the amount invested or paid for a stake is separate.
- Metric period: Undisclosed.
- Transaction value is the up-to EUR 1.95 billion cash consideration disclosed in Viatris’ July 3, 2024 Form 8-K. Previously displayed spreadsheet multiples were withdrawn because supplied public evidence did not support them.
Source summary
Viatris Form 8-K — completion of Cooper Consumer Health OTC divestiture
ConfirmedViatris disclosed up to EUR 1.95 billion cash consideration: EUR 1.85 billion at closing plus up to EUR 100 million contingent consideration.
Open source